Kevin Puylaert - 18 Mar 2026 Form 3 Insider Report for SOPHiA GENETICS SA (SOPH)

Role
Chief Sales Officer
Signature
/s/ Elimara Brunetto as Attorney-in-fact for Kevin Puylaert
Issuer symbol
SOPH
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 09:46:50 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Puylaert Kevin Chief Sales Officer C/O SOPHIA GENETICS SA, LA PIECE 12, ROLLE, SWITZERLAND /s/ Elimara Brunetto as Attorney-in-fact for Kevin Puylaert 18 Mar 2026 0002119354

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SOPH Ordinary Shares 92,419 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 10,000 $4.00 Direct F2
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 15,000 $4.21 Direct F2
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 20,000 $6.31 Direct F2
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 32,264 $18.00 Direct F2
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 10,191 $8.36 Direct F3
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 12,968 $4.72 Direct F4
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 5,921 $3.86 Direct F2
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 57,165 $4.96 Direct F5
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 28,409 $3.29 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 30,405 ordinary shares issuable upon settlement of five restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 40 ordinary shares from a March 30, 2022 grant vesting in equal monthly installments through March 30, 2026; (ii) 1,156 ordinary shares from May 18, 2022 grant vesting in equal quarterly installments through May 18, 2026; (iii) 2,640 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iv) 7,279 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (v)19,290 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
F2 The share options are fully vested and exercisable.
F3 The share option vests and becomes exercisable as to 25% of the ordinary shares on March 30, 2023, and then in equal monthly installments through March 30, 2026.
F4 The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
F5 The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
F6 The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney